Ann: Investor Presentation, page-17

I have the original research article that was listed in the main announcement for which the figures from the investor presentation were derived from. It's "Effective combination immunotherapy using oncolyticviruses to deliver CAR targets to solid tumors" (Park et al., 2020). There's a few other figures that weren't included in the presentation. I'm guessing it would be overkill and, after all, it's research which can be quite technical in nature.

Here are a few additional figures from the research article if anyone's interested. I admit it's a very polished research article. To emphasise, this is only preclinical evidence but is still promising. There's still a very long way to go for CF33 and onCARlytics and we'll be waiting some time to hear about the human safety and efficacy results for these planned studies.

Figure 4. Antitumor efficacy of combination therapy of OVm19t and mCD19-CAR T cells in an immunocompetent murine syngeneic tumor model. (Retrieved from Park et al., 2020)

(C) Right: Tumor growth was measured by noninvasive optical imaging. X indicates that mice were euthanized or had died.

• Note the combination of OVm19t + CAR appears to inhibit growth compared to the other treatment/control groups as depicted by the slower growth over time.

(D) Average tumor sizes (based on noninvasive imaging) are shown as means ± SEM.; and (E) Kaplan-Meier survival curves from the experiment described in (C).

• Note that significant survival increase for the combination of OVm19t + CAR. Sample size would have been small but the authors indicated the following "In vivo studies were performed using 6- to8-week-old NSG or C57BL/6 mice, using at least three mice pergroup for all in vivo studies, and four to nine mice were includedwithin each group for all therapy and survival studies to ensure statisticalpower." (pg. 9; Park et al., 2020)